Management Team

Management Team


p2CEO: Dr. Noam Shani
Before joining KAHR Medical in mid 2007, Dr. Shani was Vice President of R&D for Medgenics (AIM: MEDG) and for Compugen (NASDAQ: CGEN). Dr. Shani received both his master's and Ph.D. from the Weizmann Institute of Science, and did his postdoctoral research fellowships at the Johns Hopkins School of Medicine in Baltimore

Chief Scientist: Prof. Michal Dranitzki Elhalel
Professor Elhalel is Chief of nephrology and hypertension at the Hadassah Medical Center. Prof. Elhalel earned her M.D. at the Hebrew University, Hadassah Medical School and performed her Postdoctoral Fellowship in the laboratory of Professor Tykocinski at the University of Pennsylvania. Dr. Elhalel is an expert in the field of molecular immune regulation and her laboratory at Hadassah Medical Center has been fully devoted to the research of the DSP technology since 2002.

VP-Development: Dr. Moshe Baru
Before joining KAHR Medical in 2014, Dr. Baru lead drug development at Omri Laboratories for 17 years. At Omri he lead the development of LongAte, a plasma derived Factor-8 formulated with liposomes, from concept to the market place. Moshe received his doctorate from The Technion, Israel Institute of Technology.


Board Of Directors


Chairman: Dr. Kinneret Livnat Savitsky 
Dr. Savitsky was CEO of BiolineRx until October 2016. Dr. Savitsky has over 20 years of experience in early-stage drug development and in the past 12 years she held several management positions at BioLineRx, a clinical-stage, publicly-traded (NASDAQ: BLRX; TASE: BLRX) biopharmaceutical development company.

Director: Dr. Tamar Raz
Dr. Raz is CEO of Hadasit, the Technology Transfer Company of Hadassah Medical Organization (HMO) in Jerusalem, Israel. In previous position, Dr. Raz served as VP Marketing and Strategy of Ramot, the Technology Transfer Company of Tel Aviv University. Prior to joining Ramot in 2004, she directed the establishment of Allergene, an Israeli start-up company that was founded as an incubator project, and served as its CEO.

Director: Thomas Eldered
Mr. Eldered is the largest owner and CEO of Recipharm AB [RECI-B.ST], a Swedish public pharmaceutical company with a market cap of approximately $900M, employing approximately 5000 people across a number of sites in Europe, North America and Asia. He has held this position since 2008. In addition, he is non-executive director in several biotech and pharmaceutical companies.  Prior to Recipharm he was Vice President of Recip AB from 1995 to 2007 and Factory Manager at Pharmacia from 1990 to 1995. He has a M.Sc. in Industrial and Management Engineering from the Linköping Institute of Technology.

Director: Dr. Carl-Johan Spak
Dr. Spak is EVP-Development & Technology at Recipharm AB. He has been with Recipharm AB since 2009. Prior to his appointment at Recipharm he was Meda AB’s Director for the Nordic Region, from 2007 to 2008, CEO for Recip AB and Recip Läkemedel AB from 2005 to 2007, and part of the Executive Management Team for Recip AB from 1995 to 2005. Dr. Spak graduated with a Dentist degree 1980 and received his Ph.D 1984 from Karolinska Institutet, Sweden.

Director: Michel Habib
Mr. Habib is the Founder of Matar Capital Advisors. From 2007 to 2015 he was Managing General Partner of Agate Medical Investments LP and is currently Managing General Partner of Agate-MaC fund. Previously Michel served for close to 4 years as Elron Electronic Industries' Business Development Director. At Elron Mr. Habib implemented more than a dozen investments, M&A’s and represented the company on numerous Boards. Prior to Elron, he established and managed the investment banking activity of ING Barings in Israel and served as Vice President Investment Banking at Cukierman & Co. During the 90's Mr. Habib served as diplomat in Israel's foreign service, as the Economic Consul to New England in Boston, and earlier as Commercial Attaché to South Korea in Seoul. Mr. Habib holds a BsC in Aeronautical Engineering from the Technion-Israel Institute of Technology. He is a graduate from the foreign service cadet school, and member of the Technion Alumni "100 Club”. 

Director: Sangwoo Lee
Mr. Lee is an Executive Director at Korea Investment Partners Co. (KIPC). He is responsible for global expansion and activities at KIPC and manages a diverse investment portfolio; from Bio-Healthcare companies such as Elastagen and Auris Surgical Robotics, to different IT companies. Mr. Lee received his B.S and M.S in Control and Instrumental Engineering from Seoul National University and has 18 years of industrial experience in established industry leaders such as Samsung Electronics and Dasan Networks, as well as in successful venture startups such as Neomtel and Polidigm where he led the core engineering development as CTO.

Advisor to the board: Dr. Bernhard Kirschbaum
Dr. Kirschbaum was an Executive Vice-President, Global Research & Early Development at Merck Serono until the end of 2013. He has over 25 years of experience in pharmaceutical research and drug development and held leadership positions at multiple pharma giants such as Aventis, Sanofi and Merck Serono. Dr. Kirschbaum brings strong expertise in drug development in a broad range of disease areas including oncology, immuno-oncology, immunology, and neurological disorders.

Observer to the board: Mr. Jae Joon Kim
Mr. Kim is a Director of the Venture Investment Division of Mirae Asset Venture Investments. Mr. Kim successfully listed over 15 companies on the NASDAQ, KOSDAQ and KONEX, and manages a portfolio of more than 30 biopharmaceutical and diagnostics companies. Prior to Mirae Asset, Mr. Kim was a research associate at the Korean biotech Macrogen from 2002 to 2006. He holds a Master’s from the Graduate School of Medicine, Korea University.

Observer to the board: Mr. Baruch Halpert
Mr. Halpert is Chairman of the Board at Hadasit Bio-Holdings (HBL),